Cargando…

Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report

Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijikata, Yasuki, Matsubara, Yasuo, Ota, Yasunori, Lim, Lay Ahyoung, Tani, Kenzaburo, Hirata, Yoshihiro, Yotsuyanagi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/
https://www.ncbi.nlm.nih.gov/pubmed/32009094
http://dx.doi.org/10.2169/internalmedicine.3901-19
_version_ 1783530255670050816
author Hijikata, Yasuki
Matsubara, Yasuo
Ota, Yasunori
Lim, Lay Ahyoung
Tani, Kenzaburo
Hirata, Yoshihiro
Yotsuyanagi, Hiroshi
author_facet Hijikata, Yasuki
Matsubara, Yasuo
Ota, Yasunori
Lim, Lay Ahyoung
Tani, Kenzaburo
Hirata, Yoshihiro
Yotsuyanagi, Hiroshi
author_sort Hijikata, Yasuki
collection PubMed
description Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings.
format Online
Article
Text
id pubmed-7205527
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-72055272020-05-12 Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report Hijikata, Yasuki Matsubara, Yasuo Ota, Yasunori Lim, Lay Ahyoung Tani, Kenzaburo Hirata, Yoshihiro Yotsuyanagi, Hiroshi Intern Med Case Report Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings. The Japanese Society of Internal Medicine 2020-02-01 2020-04-15 /pmc/articles/PMC7205527/ /pubmed/32009094 http://dx.doi.org/10.2169/internalmedicine.3901-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hijikata, Yasuki
Matsubara, Yasuo
Ota, Yasunori
Lim, Lay Ahyoung
Tani, Kenzaburo
Hirata, Yoshihiro
Yotsuyanagi, Hiroshi
Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title_full Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title_fullStr Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title_full_unstemmed Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title_short Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
title_sort safe use of nivolumab in a patient with epipharyngeal carcinoma and preexisting ulcerative colitis: a histologically proven case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/
https://www.ncbi.nlm.nih.gov/pubmed/32009094
http://dx.doi.org/10.2169/internalmedicine.3901-19
work_keys_str_mv AT hijikatayasuki safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT matsubarayasuo safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT otayasunori safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT limlayahyoung safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT tanikenzaburo safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT hiratayoshihiro safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport
AT yotsuyanagihiroshi safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport